A biotech up­start just scored $103M from Pfiz­er et al to fu­el its pur­suit of a new (to you) I/O path­way

It isn’t like­ly you’ve heard a lot about Im­Check Ther­a­peu­tics.

Its main base in Mar­seille is close to the sci­ence it’s pur­su­ing, far from the bio­phar­ma main­stream. There are some snip­pets of hu­man da­ta, but much of the pub­lished work on their tech­nol­o­gy is from pre­clin­i­cal ef­forts in­volv­ing mice. And who ever spot­light­ed bu­ty­rophilins be­fore?

But CEO Pierre d’Epe­noux — an ex­pe­ri­enced in­dus­try BD hand who com­plet­ed a stint at Sanofi — is out to change that on-the-fringe sta­tus with the $103 mil­lion round that he’s just bagged for the biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER